If you believe the large pharmaceutical companies whose work revolves in large part to non-profit projects. After all, they had “social responsibility”, were following on the “important missions” and had a “role model”, as it says on the websites of various companies in the industry.

The commitment of Bayer and co. however, according to an Access to Medicine Reports. The researchers of the eponymous Dutch Non-Profit organization examining all of the two years in the extent to which the 20 biggest pharmaceutical companies in the world seek the medical care of developing countries.

Although companies have expanded their aid programmes, have brought new medicines to the market and offered fairer prices, but all in all, the result is this Time too sobering. Only five of the twenty largest pharmaceutical companies to develop according to the Report, currently, the drugs that are needed in the poorest countries.

The British company GlaxoSmithKline is leading for the sixth Time in a row the Ranking. The U.S. group, Johnson Johnson, Novartis of Switzerland, the German family company Merck, as well as the French Sanofi are among the companies that invest the most in research and development of urgently needed medicines. Together, they are 63 per cent of all projects of this kind.

Half of the research focused on five diseases

The fact that a handful of companies bear the majority of high-priority research and development, shows how fragile the Situation is, said Jayasree Iyer, managing Director of Access to Medicine to the world newspaper. A withdrawal of only one of these companies would have a significant impact.

The report also shows that 50 percent of the research projects of the 20 largest pharmaceutical companies, only five diseases. Because of Malaria, Aids, tuberculosis, leishmaniasis and Chagas disease as the most common diseases in poor countries, research projects in those areas of easier financial support of international donors and health initiatives.

Bayer on place 16

Studies about diseases that are less common and therefore lead to a lesser public interest are often placed in the Background. These include diseases such as the virus disease Crimean-Congo haemorrhagic fever, whose Transmission is effected by ticks but also from person to person. Currently, there are the Crimean-Congo fever, no Medicine. Also the carry Lassa fever or of infectious disease, Nipah and the Zikavirus researchers pay hardly attention to it.

If the society of the priorities is aware of helps to focus the efforts of the industry, said Danny Edwards, research Director of the Index, compared to the world. In short: if there is a call to Action or donations, engage more businesses, particularly in areas with low commercial potential.

Among the German companies Merck cuts off at the best and evidenced in the total ranking of four. The family-owned company Boehringer Ingelheim was able to improve by two places to rank 14. Only Bayer could show no Upward Trend. The largest German pharmaceutical company slipped four places down and is now in 16th place.